Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 2/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EEF2K | O00418 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7702501 | 1.00 | NAT1 (0.70) | NAT1PTGS2PTGS1ALOX5MEN1 | |
| SCHEMBL8532901 | 0.86 | NAT1 (0.58) | NAT1MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL8532902 | 0.86 | NAT1 (0.58) | NAT1MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL7246589 | 0.85 | NAT1 (0.69) | NAT1PTGS2PTGS1ALOX5MEN1 | |
| SCHEMBL7246592 | 0.85 | NAT1 (0.69) | NAT1PTGS2PTGS1ALOX5MEN1 | |
| SCHEMBL8198993 | 0.85 | NAT1 (0.69) | NAT1PTGS2PTGS1ALOX5MEN1 | |
| SCHEMBL8534268 | 0.82 | PTGS2 (0.55) | NAT1PTGS2PTGS1ALOX5MEN1 | |
| SCHEMBL8534273 | 0.82 | PTGS2 (0.55) | NAT1PTGS2PTGS1ALOX5MEN1 | |
| SCHEMBL8933323 | 0.80 | PTGS2 (0.56) | NAT1PTGS2PTGS1ALOX5MEN1 | |
| SCHEMBL8895510 | 0.80 | PTGS2 (0.56) | NAT1PTGS2PTGS1ALOX5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420428-B1 | TREATING HEPATITIS C AND HEPATIC FIBROSIS USING 2,6-DI-TERT-BUTYLPHENOL DERIVATIVES; EFFECTIVE IN SUBJECTS WITH INTERFERON INSUSCEPTIBILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-07-16 | — | — | US | disclosed |
| US-6369097-B1 | Treatment and prevention of hepatic disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-09 | — | — | US | disclosed |
| US-6348493-B1 | TREATMENT OF HEPATITIS C BY ADMINISTERING 2,6-DI-TER-BUTYLPHENOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-02-19 | — | — | US | disclosed |
| US-6218437-B1 | ADMINISTERING A THERAPEUTIC AMOUNT OF DI-TERT-BUTYLPHENOL DERIVATIVE TO SUBJECT UNDER CONDITIONS SUCH THAT SAID SYMPTOMS ARE DIMINISHED | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-04-17 | — | — | US | disclosed |
| WO-2001021166-A1 | TREATMENT AND PREVENTION OF HEPATIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-03-29 | — | — | WO | disclosed |
| EP-0434394-B1 | Compounds for treating inflammatory bowel disease | LILLY CO ELI (US) | 1998-08-05 | — | — | EP | disclosed |
| EP-0722729-A2 | Aryl-substituted rhodanines for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5356917-A | Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| EP-0434394-A2 | Compounds for treating inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |